TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25959271
Drug: Spironolactone 50
Normalized name: spironolactone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 50 mg daily for six weeks
Study: 19567528
Drug: Testosterone low
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone low dose (T-LD) 0.75 mg/12 h iv
Study: 19567528
Drug: Testosterone high
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone high dose (T-HD) 2.5 mg/12 h iv
Study: 11775648
Drug: Essaven gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essaven gel (EG) applied locally for 2 weeks
Study: 7746029
Drug: Bretazenil 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bretazenil 0.25 mg
Study: 7746029
Drug: Bretazenil 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bretazenil 0.5 mg
Study: 30084098
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of honey on oral mucosa
Study: 30084098
Drug: Routine practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine practice of analgesic and antiseptic gel application (Control)
Study: 28615010
Drug: Internet-based perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based perioperative exercise program (iPEP), including daily endurance, resistance and ventilation training.
Study: 26147236
Drug: Cognitive Symptom
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Symptom Management and Rehabilitation Therapy (CogSMART), a 12‐session, manualized compensatory cognitive training intervention
Study: 9186317
Drug: 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg OTZ
Study: 9186317
Drug: 70 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg/kg OTZ
Study: 8383319
Drug: Glyceryltrinitrate (GTN)
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyceryltrinitrate (GTN) ointment
Study: 8383319
Drug: Heparinoid ointment
Normalized name: heparinoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparinoid ointment (Control)
Study: 3022628
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate (AB) 1.5 mg/kg
Study: 27171324
Drug: Albuterol (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (9 puffs for up to 15 kg, 12 puffs for >15-20 kg, 15 puffs for >20-25 kg, 18 puffs for >25 kg)
Study: 27171324
Drug: Albuterol (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (various dosages as per weight)
Study: 23328180
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of mitomycin-C (0.4 mg/ml) adjuncted with interventional bronchoscopy
Study: 11563410
Drug: Nateglinide 60
Normalized name: nateglinide 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 60 mg administered 10 minutes before a high-fat breakfast meal
Study: 11563410
Drug: Nateglinide 60
Normalized name: nateglinide 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 60 mg administered immediately after a high-fat breakfast meal
Study: 11563410
Drug: Nateglinide 30
Normalized name: nateglinide 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 30 mg and 60 mg under fasting conditions
Study: 1819709
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 2.16 g per day for 4 weeks
Study: 1819709
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil 12 g per day for 4 weeks
Study: 7288877
Drug: Behavioral contracting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral contracting (with or without family involvement) and weekly telephone contacts
Study: 30160369
Drug: Standard postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard postoperative G‐tube care
Study: 30160369
Drug: Standard hydrocolloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hydrocolloid G‐tube dressing
Study: 30160369
Drug: Silver‐impregnated hydrocolloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver‐impregnated hydrocolloid G‐tube dressing
Study: 27756804
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis (IVT) and adjunctive intra-arterial mechanical thrombectomy (MT)
Study: 23535007
Drug: Preoperative ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preoperative ibuprofen continued for a week
Study: 23535007
Drug: Preoperative ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preoperative ibuprofen continued for a week + Intraoperative dexamethasone
Study: 21112746
Drug: Fluoxetine 20mg
Normalized name: fluoxetine 20 MG
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine 20mg uid
Study: 19734682
Drug: Heat-killed Lactobacillus
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-killed Lactobacillus gasseri OLL2809 (100 mg per day for 8 weeks)
Study: 16118723
Drug: Glycerin suppository
Normalized name: Leader Pediatric Glycerin Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerin suppository
Study: 11275800
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream applied to the ulcer for 30-45 minutes under occlusion
Study: 9428981
Drug: Dimethindene maleate
Normalized name: dimethindene maleate
DrugBank: Dimetindene (DB08801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethindene maleate (DMM) 0.1 mg/kg x d
Study: 9428981
Drug: Dimethindene maleate
Normalized name: dimethindene maleate
DrugBank: Dimetindene (DB08801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethindene maleate (DMM) 0.05 mg/kg x d
Study: 3755517
Drug: Vitamin D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin D2 supplement of 1000 IU/day during the last three months of pregnancy
Study: 3755517
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 5 mg at the seventh month of pregnancy
Study: 31243706
Drug: Time series
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time series regressions using lagged inputs after treatment initiation
Study: 25494702
Drug: EmPhAsIS intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EmPhAsIS intervention (patient asthma education, SMS-based monthly adherence assessment, follow-up by pharmacists)
Study: 20882405
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 1 mg IV weekly for 4 doses
Study: 20882405
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of zoledronic acid 4 mg IV
Study: 20882405
Drug: Metronomic low‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic low‐dose zoledronic acid
Study: 10489950
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL bivalent intravenous scorpion antivenom
Study: 30385397
Drug: Topical emollient
Normalized name: HPR Topical Emollient Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical emollient
Study: 19509162
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral docetaxel with ritonavir
Study: 19509162
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral docetaxel with ritonavir (simultaneously)
Study: 19509162
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral docetaxel with ritonavir (60 minutes before)
Study: 17311980
Drug: Probiotics with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics with standard antibiotic treatment
Study: 10327910
Drug: Fluvoxamine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (mean daily dose 202 mg, SD = 86)
Study: 6980782
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy with bacterial allergens (E. coli, proteus, staphylococcus, streptococcus)
Study: 26962728
Drug: Three-dose dihydroartemisinin‐piperaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose dihydroartemisinin‐piperaquine (94 participants)
Study: 26962728
Drug: Monthly dihydroartemisinin‐piperaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly dihydroartemisinin‐piperaquine (100 participants)
Study: 24732918
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg verapamil
Study: 12882706
Drug: Routine chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine chemotherapy plus thalidomide (A)
Study: 12882706
Drug: Routine chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine chemotherapy alone (B)
Study: 12882706
Drug: Routine chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine chemotherapy plus thalidomide (C) for relapsing cases
Study: 6414626
Drug: Leaflet provided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leaflet provided to patients prescribed non-steroidal anti-inflammatory drugs (43 patients)
Study: 6414626
Drug: No leaflet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No leaflet provided (Control group: 65 patients prescribed penicillin and 33 prescribed non-steroidal anti-inflammatory drugs)
Study: 30831101
Drug: Mepivacaine 1%
Normalized name: mepivacaine 1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine 1% 10 mL intrauterine instillation
Study: 25736569
Drug: Anodal tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodal tDCS and conventional physical therapy
Study: 25736569
Drug: Sham stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham stimulation and conventional physical therapy
Study: 21883497
Drug: Dietary manganese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary manganese concentration of 0.24 mg/kg
Study: 21883497
Drug: Dietary manganese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary manganese concentration of 2 mg/kg
Study: 21883497
Drug: Dietary manganese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary manganese concentration of 4 mg/kg
Study: 21883497
Drug: Dietary manganese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary manganese concentration of 16 mg/kg
Study: 21883497
Drug: Dietary manganese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary manganese concentration of 32 mg/kg
Study: 24777136
Drug: Antiepileptic medication
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic medication
Study: 30683080
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CT group) maintaining original treatment (tiotropium and/or budesonide/formoterol)
Study: 21824709
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of u-hCG
Study: 19061964
Drug: Speech pathology
Normalized name: TRACH TUBE,SPEECH SZ 10 BLOM #313-30-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech pathology intervention (multidimensional treatment programme including education, vocal hygiene training, cough suppression strategies, psychoeducational counseling)
Study: 16696745
Drug: Risedronate 30
Normalized name: risedronate 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 30 mg once weekly for 12 weeks
Study: 16696745
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 400 IU daily
Study: 7920871
Drug: L-dopa with
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa with pyridostigmine pretreatment in obese subjects
Study: 7920871
Drug: L-dopa with
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa with pyridostigmine pretreatment in control subjects
Study: 7920871
Drug: L-dopa only
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa only in obese subjects
Study: 7920871
Drug: L-dopa only
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa only in control subjects
Study: 7920871
Drug: Plasma insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma insulin and FFA levels in obese subjects
Study: 18462564
Drug: FSC 100/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSC 100/50 mcg
Study: 18462564
Drug: FP 100
Normalized name: Peanut Allergen-dnfp 100 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP 100 mcg
Study: 15748068
Drug: Home visits
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home visits by trained members of the Iraqi Women's Federation during the 2-month initial phase of DOTS treatment
Study: 15748068
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group attending local health centre for treatment
Study: 1034720
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.25% mepivacaine
Study: 1034720
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.25% mepivacaine containing CH3 B12 1,000 μg
Study: 1034720
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of physical saline solution containing CH3 B12 1,000 μg
Study: 1034720
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.5% procaine
Study: 1034720
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.5% procaine containing CH3 B12 1,000 μg
Study: 23588944
Drug: Apremilast 40
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast 40 mg QD
Study: 8400608
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (500 mg/day calcium intake)
Study: 24812434
Drug: Intensive glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose treatment group
Study: 2015151
Drug: Trimetaphan 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetaphan 0.05 mg kg‐1
Study: 2015151
Drug: Trimetaphan 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetaphan 0.1 mg kg‐1
Study: 6461678
Drug: Isotretinoin therapy
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin therapy (13‐cis‐retinoic acid) discontinued for at least 20 weeks
Study: 30834647
Drug: Comprehensive medication
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive medication reviews (CMRs) by ward-based pharmacists including follow-up telephone calls after hospital discharge.
Study: 30769063
Drug: Heparin-bonded PTFE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded PTFE graft
Study: 21389859
Drug: Emergency medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency medicine rotation (theoretical and practical course)
Study: 11848262
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg perindopril and 0.625 mg indapamide
Study: 11848262
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg indapamide
Study: 11848262
Drug: Combination vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination vs Losartan
Study: 10437260
Drug: Point-injection group
Normalized name: meningococcal group B vaccine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point-injection group
Study: 3279578
Drug: Azathioprine +
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine + low-dose steroids
Study: 19671875
Drug: Chemotherapy (cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cyclophosphamide, i.v. methotrexate, and 5-fluorouracil or cyclophosphamide, i.v. doxorubicin, and 5-fluorouracil +/- tamoxifen)
Study: 17116185
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg lipo‐PGE(1) given as a continuous infusion over 5 days, along with 48 mg methylprednisolone for 5 days
Study: 17116185
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (placebo) along with 48 mg methylprednisolone for 5 days
Study: 11727357
Drug: E2 +
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2 + TMG (2 mg estradiol and 0.5 mg trimegestone)
Study: 9135704
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg oxandrolone daily
Study: 9135704
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg testosterone monthly intramuscular injections
Study: 3070420
Drug: Intravenous Nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Nimodipine
Study: 18753471
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg of morphine plus saline solution (MO)
Study: 18753471
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg of morphine plus a 5-mg ketamine bolus (MK)
Study: 17242418
Drug: Combined treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatments (psychosocial and pharmacological)
Study: 14684584
Drug: VSL#3 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: VSL#3 6 g once daily for one year
Study: 14684584
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for one year
Study: 12116511
Drug: Discontinuance of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuance of the whitening agent
Study: 2252171
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia with methohexital and fentanyl
Study: 31282768
Drug: TX‐001HR (1/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: TX‐001HR (1/100 mg, 0.5/100 mg, 0.5/50 mg, 0.25/50 mg)
Study: 31282768
Drug: TX‐001HR (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: TX‐001HR (1 mg/100 mg)
Study: 22324056
Drug: Compensation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compensation group treatment programme
Study: 22324056
Drug: Restitution group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restitution group treatment programme
Study: 19438472
Drug: G-CSF (Lenograstim,
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (Lenograstim, 263 microg/d)
Study: 17263856
Drug: Xylitol-containing chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol-containing chewing gum (total dose=6.18 g/day)
Study: 11427330
Drug: Oral rizatriptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rizatriptan 5 mg
Study: 2140663
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2 mg cyproterone acetate (CPA) with 0.035 mg ethinyl estradiol (EE) (Diane 35)
Study: 2140663
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.150 mg desogestrel (DG) with 0.03 mg ethinyl estradiol (EE) (Marvelon)
Study: 19368512
Drug: Topical vitamin
Normalized name: vitamin A Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vitamin B(12)
Study: 17516069
Drug: Milataxel (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milataxel (35 mg/m², administered intravenously every 3 weeks)
Study: 15477049
Drug: Intrathecal 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 0.5% bupivacaine 7.5 mg with saline 1 mL (group B)
Study: 15477049
Drug: Intrathecal 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 0.5% bupivacaine 7.5 mg with fentanyl 10 microg (group Bf10)
Study: 15477049
Drug: Intrathecal 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 0.5% bupivacaine 7.5 mg with fentanyl 20 microg (group Bf20)
Study: 11926203
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of ascorbic acid (AA) daily for four weeks
Study: 1233216
Drug: Propranolol (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.06 mg/kg i.v.)
Study: 1233216
Drug: Metoprolol (0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (0.12 mg/kg i.v.)
Study: 1233216
Drug: Isoprenaline (increasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprenaline (increasing doses)
Study: 31486684
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with Deferoxamine (DFO) and Deferasirox (DFX)
Study: 22713632
Drug: Alfentanil (μ‐opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (μ‐opioid receptor agonist)
Study: 15890794
Drug: Graded doses
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded doses of a selective gonadotropin releasing hormone (GnRH)‐receptor antagonist
Study: 12523577
Drug: Antithymocyte globulin
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithymocyte globulin (ATG) 7.5 to 15 mg/kg
Study: 9713561
Drug: Induced hypocalcaemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induced hypocalcaemia (blood ionized calcium lowered by 0.20 mmol/l within 30 min)